USS Investment Management Ltd Buys 915 Shares of Regeneron Pharmaceuticals, Inc. $REGN

USS Investment Management Ltd increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,230 shares of the biopharmaceutical company’s stock after buying an additional 915 shares during the quarter. USS Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $15,626,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. IFM Investors Pty Ltd raised its holdings in Regeneron Pharmaceuticals by 1.4% in the 1st quarter. IFM Investors Pty Ltd now owns 21,032 shares of the biopharmaceutical company’s stock valued at $16,250,000 after acquiring an additional 294 shares in the last quarter. Element Squared LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $2,269,000. MQS Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $225,000. Eagle Wealth Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $210,000. Finally, Premier Path Wealth Partners LLC increased its position in shares of Regeneron Pharmaceuticals by 24.2% in the first quarter. Premier Path Wealth Partners LLC now owns 667 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 130 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. cut their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Finally, Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $792.65.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ REGN opened at $624.72 on Thursday. The company has a market cap of $66.05 billion, a price-to-earnings ratio of 15.22, a PEG ratio of 1.37 and a beta of 0.24. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $529.69 and a 12 month high of $821.11. The stock has a 50-day moving average price of $656.18 and a two-hundred day moving average price of $726.61.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same period last year, the company posted $8.22 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.